Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973674 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2EPHX2CTSKEPHX1 | |
| SCHEMBL1684776 | 0.82 | CTSS (0.43) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL5751932 | 0.81 | USP2 (0.44) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL15461484 | 0.80 | CTSK (0.40) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL19625230 | 0.80 | EPHX2 (0.39) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL388054 | 0.80 | USP2 (0.46) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL22576321 | 0.80 | KDM4E (0.45) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL18319117 | 0.80 | CTSL (0.43) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL2887782 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2EPHX2CTSKJAK2 | |
| SCHEMBL1118226 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2EPHX2CTSKEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250145643-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-05-08 | — | — | US | disclosed |
| CN-119798279-A | RAS inhibitors | 锐新医药公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-118922423-A | RAS inhibitors | 锐新医药公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118561952-A | RAS inhibitors | 锐新医药公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118234731-A | RAS inhibitors | 锐新医药公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | USP2 2484/4885SMN1; SMN2 4241/4885EPHX2 1934/4885 |
| US-20250145643-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | USP2 1149/4885SMN1; SMN2 3728/4885EPHX2 3033/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | USP2 2102/4885SMN1; SMN2 4495/4885EPHX2 2202/4885 |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | USP2 3336/4885SMN1; SMN2 3830/4885EPHX2 2528/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | USP2 2102/4885SMN1; SMN2 4495/4885EPHX2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.